ResearcherThe University of Kansas Cancer CenterNo recent work listed
Animesh Dhar
Matched on ORCID iD 0000-0003-2249-9191; OpenAlex author ID A5101512849; NIH RePORTER profile ID 8132894. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 14
2011: 1 paper · 2012: 1 grant · 2013: 1 grant · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper
Papers 5
- Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2019.11.279↗
- Super-enhancers: novel target for pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.26704↗
- Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Co-author DOI 10.18632/oncotarget.6560↗
- Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells. Last author DOI 10.18632/oncotarget.4871↗
- 3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis. Co-author DOI 10.1158/1535-7163.mct-11-0399↗
Grants 2
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dharmalingam Subramaniam · 5 shared papers, 2011–2020 · strength 0.30
- Paper Super-enhancers: novel target for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.26704↗
- Paper Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal … DOI 10.1053/j.gastro.2019.11.279↗
- Paper Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. DOI 10.18632/oncotarget.6560↗
- Shrikant Anant · 5 shared papers, 2011–2020 · strength 0.30
- Paper Super-enhancers: novel target for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.26704↗
- Paper Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal … DOI 10.1053/j.gastro.2019.11.279↗
- Paper Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. DOI 10.18632/oncotarget.6560↗
- Prasad R. Dandawate · 3 shared papers, 2016–2020 · strength 0.23
- Paper Super-enhancers: novel target for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.26704↗
- Paper Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal … DOI 10.1053/j.gastro.2019.11.279↗
- Paper Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. DOI 10.18632/oncotarget.6560↗
- Chandrayee Ghosh · 2 shared papers, 2019–2020 · strength 0.18
- Subhash Padhyé · 3 shared papers, 2015–2020 · strength 0.17
- Paper Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal … DOI 10.1053/j.gastro.2019.11.279↗
- Paper Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. DOI 10.18632/oncotarget.6560↗
- Paper Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells. DOI 10.18632/oncotarget.4871↗
- Rakesh K. Srivastava · 1 shared grant, 2012 · strength 0.13
- Weijing Sun · 1 shared paper, 2020 · strength 0.08
- Domenico Coppola · 1 shared paper, 2020 · strength 0.08
- Mokenge Peter Malafa · 1 shared paper, 2020 · strength 0.08
- Anup Kasi · 1 shared paper, 2020 · strength 0.08
- Danny R. Welch · 2 shared papers, 2011–2015 · strength 0.07
- Sivapriya Ponnurangam · 1 shared paper, 2016 · strength 0.05
- Sitaram Harihar · 1 shared paper, 2015 · strength 0.04
- Parthasarathy Rangarajan · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.